Summary
The present study was undertaken to determine if prior administration of zinc acetate (ZnAc) or copper sulfate (CuSO4) could prevent pituitary, Leydig, or Sertoli cell dysfunction subsequent to cisplatin administration in adult Sprague-Dawley rats. Animals were given cisplatin at a dose of 2 mg/kg daily for 5 days, with or without the i.p. administration of ZnAc (6 mg/kg per day) or CuSO4 (5 mg/kg per day), beginning 5 days prior to and continuing through the administration of cisplatin. Control animals were given vehicle, ZnAc1, or CuSO4. Animals were sacrificed 1 week after the initial cisplatin injection. Cisplatin administration resulted in suppressed serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels as well as a 77% reduction in serum testosterone and an 82% reduction in testicular testosterone. The concomitant administration of either ZnAc or CuSO4 did not result in a significant difference relative to animals receiving cisplatin alone, although administration of both cations alone significantly reduced testicular testosterone content. Serum androgen-binding protein (ABP) was not significantly lowered in any treatment group. There was a marked reduction of 57% in testicular ABP content relative to control values subsequent to cisplatin administration. This reduction was partially prevented by ZnAc treatment; the testicular ABP concentration was only 15% lower than that in controls (not significant). Since the cisplatin-induced reduction in serum FSH was not altered by ZnAc pretreatment, we conclude that the near normalization of testicular ABP content may be evidence of improved Sertoli cell function. In contrast, cisplatin-induced decreases in the serum gonadotropins and testicular androgens were not lessened by pretreatment with either cation. Further studies may be warranted to determine whether ZnAc pretreatment has a beneficial effect on spermatogenesis during cisplatin treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berthelsen JG, Skakkebaek NE (1983) Gonadal function in men with testis cancer. Fertil Steril 39: 93–98
Chellman G, Shaikh ZA, Baggs RB, Diamond GL (1985) Resistance to cadmium-induced necrosis in testes of inbred mice: possible role of a metallothionein-like cadmium-binding protein. Toxicol Appl Pharmacol 79: 511–523
Corden BJ, Fine RL, Ozols RF, Collins JM (1985) Clinical pharmacology of high dose cisplatin. Cancer Chemother Pharmacol 14: 38–41
Guarino AM, Miller DS, Arnold ST (1979) Platinate toxicity: past, present and prospects. Cancer Treat Rep 63: 1475–1483
Gunn SA, Gould TC, Anderson WAD (1961) Hormonal control of zinc in mature rat testis. J Endocrinol 23: 37–43
Gunsalus GL, Musto NA, Bardin CW (1978) Immunoassay of androgen binding protein in blood: a new approach for study of the seminiferous tubule. Science 200: 65–67
Gunsalus GL, Larrea F, Musto NA, Becker RR, Mather JP, Bardin CW (1981) Androgen binding proteins as a marker for Sertoli cell function. J Steroid Biochem 15: 99–105
Huang HFS, Nieschlag E (1986) Suppression of the intratesticular testosterone is associated with quantitative changes in spermatogonial populations in intact adult rats. Endocrinology 118: 619–627
Levi J, Jacobs C, Kalman SM, McTigue M, Weiner JW (1980) Mechanism of cis-platinum nephrotoxicity: 1. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213: 545–550
Loehrer JP, Einhorn LH (1984) Cisplatin. Ann Int Med 100: 704–713
Maines MD, Mayer RD (1985) Inhibition of testicular cytochrome P-450-dependent steroid biosynthesis by cisplatinum. J Biol Chem 250: 6063–6068
Naganuma A, Satoh M, Imura N (1984) Effect of copper pretreatment on toxicity and antitumor activity of cis-diamminedichloroplatinum in mice. Res Commun Chem Pathol Pharmacol 46: 265–274
Naganuma A, Satoh M, Koyama Y, Imura N (1985) Protective effect of metallothionein inducing metals on lethal toxicity of cis-diamminedichloroplatinum in mice. Toxicol Lett 24: 203–207
Pogach L, Lee Y, Giglio W, Huang FHS (1985) Leydig cell dysfunction following cisplatin administration in Sprague Dawly rats (Abstract). American Federation for Clinical Research, Washington, DC
Pogach LM, Lee Y, Gould S, Giglio W, Meyenhofer M, Huang HFS (1989) Characterization of cisplatinum induced Sertoli cell dysfunction in rodents. Toxicol Appl Pharmacol (in press)
Preece A (ed) (1972) A manual for histologic technicians. Little, Brown and Company, Boston
Roberts JJ (1982) Cisplatin. In: Pinedo HM (ed) Cancer chemotherapy. Excerpta Medica, Amsterdam, pp 95–117
Rosenberg B, VanCamp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698–699
Sharma RP (1984) Cisplatinum: effect of zinc acetate pretreatment on cellular uptake and interactions with cytosolic ligands. Toxicology 32: 75–84
Sharma RP (1985) Interactions of cis-platinum with cellular zinc and copper in rat liver and kidney tissues. Pharmacol Res Commun 17: 197–210
Solecki TJ, Avia A, Bogden JD (1984) Effect of a chelating drug on balance and tissue distribution of four essential metals. Toxicology 31: 107–116
Taylor DM, Jones JD, Robins AB (1973) Metabolism of platinum 14C-ethylenediamine dichloride in the rat. Biochem Pharmacol 22: 831–839
Timm F, Schulz G (1966) Hoden und Schwermetalle. Histochemie 7: 15–27
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pogach, L.M., Lee, Y., Giglio, W. et al. Zinc acetate pretreatment ameliorates cisplatin-induced Sertoli cell dysfunction in Sprague-Dawley rats. Cancer Chemother. Pharmacol. 24, 177–180 (1989). https://doi.org/10.1007/BF00300239
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00300239